Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C – real-world data from the German observational, prospective, nation-wide CRISP Registry (AIO-TRK-0315)

Griesinger F, Eberhardt WEE2, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, Alt J, Schütte W, Jänicke M, Fleitz A, Zacharias S, Hipper A, Buller M, Weichert W, Groschek M, von der Heyde E, Rauh J, Dechow T, Sebastian M, Thomas M, 2020

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: -
CRISP
2020
What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL

A. Welt, M. Thill, E. Stickeler, M.-O. Zahn, A. Nusch, M. Zaiss, U. Neef, S. Fruehauf, R. Buss-Steidle, V. Hagen, M. Chiabudini, L. Kruggel, M. Jänicke, N. Marschner, A. Wöckel, N. Harbeck, T. Decker, 2020

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: -
OPAL
2020
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

Staehler, M, Panic, A, Goebell, PJ, Merling, M, Potthoff, K, Herrmann, E, de Geeter, P, Vannier, C, Hogrefe, C, Marschner, N, Grünwald, V, 2020.

Int J Cancer. 2020;1-11.

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: / Journal: International Journal of Cancer
FLIPPER
2020
Patient, nurse and physician preferences: Final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or On-body injector (OBI) in cancer patients

M. Metz, D. Semsek, G. Rogmans, U. Hutzschenreuter, T. Fietz, J. Harde, S. Zacharias, C. Hielscher, A. Lorenz, M.-O. Zahn, D. Guth, S. Grebhardt, C. Fichter, K. Potthoff, 2020.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: -
CONVENIENCE
2020
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.

Link, H.,, Illerhaus, G., Martens, U. M., Salar, A., Depenbusch, R., Köhler, A., Engelhardt, M., Mahlmann, S., Zaiss, M., Lammerich, A., Bias P., Buchner, A.

Abstract

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: / Journal: Supportive Care in Cancer
AVOID
2020
Rare patients in routine care: Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL

Thill M., Zahn M.-O., Welt A., Stickeler E., Nusch A., Fietz T., Rauh J., Wetzel N., Kruggel L., Jänicke M., Marschner N., Harbeck N., Wöckel A., Decker T., OPAL Registergruppe

Cancer Res (2021) 81 (4_Supplement): PS11-16.

Abstract

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
OPAL
2020
REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).

Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020.

HemaSphere 4(S1) (EP1245), 583.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: HemaSphere
REFLECT
2020
REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).

Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020.

J Clin Oncol 38 no. 15_suppl (May 20, 2020) 8060-8060. DOI: 10.1200/JCO.2020.38.15_suppl.8060

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
REFLECT
2020
Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study.

Dechow T, Riera-Knorrenschild J, Hackanson B, Fischer von Weikersthal L, Schulz H, Chiabudini M, Timm B, Zerbes R, Potthoff K, 2020.

J Clin Oncol 38: 2020 (suppl; abstr e21611) doi: 10.1200/JCO.2020.38.15_suppl.e21611

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
NEPTUN
2020
Dynamics in the choice of treatment for patients with Multiple Myeloma – Results from the MYRIAM registry.

Engelhardt, M., Knauf, W., Lipke, J., Reiser, M., Dörfel, S., Kortüm, M., Schlag, R., von der Heyde, E., La Rosée, P., Pfannes, R., Lamberti, C., Houet, L., Medinger, T., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2020.

HemaSphere 4(S1)(EP994), 454–455.

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: EHA / Journal: HemaSphere
MYRIAM
2020